Posted on 06/11/2008 in Pharmaceutical Company Product News Bristol-Myers Squibb has published design and rationale of the Current-Oasis 7 study in the American Heart Journal.
The research, into coronary intervention acute coronary syndrome (ACS) patients, is set to evaluate the efficacy and safety of higher loading and initial maintenance doses of Plavix (clopidogrel bisulfate).
The work will also analyse the effects of aspirin on cardiovascular outcomes and bleeding complications in patients with ACS who are due to undergo intervention with coronary angioplasty.
Principal investigator, Shamir Mehta, said: "Current-Oasis 7 will provide critical information on whether the effects of a more intensive clopidogrel loading dose and initial maintenance regimen is superior to the standard treatment of ACS patients undergoing Percutaneous Coronary Intervention (PCI) and may improve outcomes."
Current Oasis 7 is planned to engage between 18,000 and 20,000 patients who suffer from ACS symptoms and are scheduled to undergo the surgery, with intent to perform PCI as soon as possible.
Based in New York, Bristol-Myers Squibb was formed in 1887, following the acquisition of Clinton Pharmaceutical Company.
The company sold its Medical Imaging business to Avista Capital Partners for $525 million (329 million pounds) in January 2008. It now works in research and development of treatments including rheumatoid arthrtitis, obesity, HIV, Aids and cancer.Other news stories from 06/11/2008
Read more in the Zenopa News Archive
How this news is generated
|
